Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Vera Therapeutics, Inc.

31.77
-1.9000-5.64%
Post-market: 32.020.2500+0.79%16:23 EDT
Volume:3.91M
Turnover:125.38M
Market Cap:2.28B
PE:-5.39
High:34.00
Open:33.22
Low:31.19
Close:33.67
52wk High:56.05
52wk Low:23.05
Shares:71.71M
Float Shares:52.39M
Volume Ratio:1.03
T/O Rate:7.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.8984
EPS(LYR):-4.6644
ROE:-91.75%
ROA:-46.76%
PB:5.59
PE(LYR):-6.81

Loading ...

OverviewCompanyNewsFilings

Analysts Offer Insights on Healthcare Companies: Viatris (VTRS) and Vera Therapeutics (VERA)

TIPRANKS
·
Yesterday

U.S. Stocks on the MOVE-Forgent Power, Vera Bradley, Wells Fargo

Reuters
·
Yesterday

Top Midday Stories: Waystar Reportedly Mulling Potential Sale; Intel-Backed Altera Says Parent Company Files Confidentially for IPO

MT Newswires Live
·
Sep 15

Rami Katkhuda Reiterates Buy on Trutakna, Citing Strong Clinical and Early Commercial Traction; $90 Price Target Maintained

TIPRANKS
·
Sep 15

Vera Therapeutics ORIGIN 3 study results positive, says Raymond James

TIPRANKS
·
Sep 15

Vera Therapeutics Shares up 1.5% After Kidney Disease Drug Meets Goals in Confirmatory Trial

THOMSON REUTERS
·
Sep 15

U.S. Stocks on the MOVE-Eli Lilly, Waystar, Sysco

Reuters
·
Sep 15

Vera Therapeutics Shares Gain on Positive Late-Stage Trial Results

Dow Jones
·
Sep 15

Vera Therapeutics Reports Successful TRUTAKNA Phase 3 Results

TIPRANKS
·
Sep 15

Top Premarket Gainers

MT Newswires Live
·
Sep 15

Vera Therapeutics up 13% in pre-market at $38.63 after trutakna ORIGIN 3 data

TIPRANKS
·
Sep 15

Vera Therapeutics Gains After Kidney Disease Drug Meets Goals in Confirmatory Trial

Reuters
·
Sep 15

Vera Therapeutics’ trutakna meets all efficacy endpoints in IgAN trial

TIPRANKS
·
Sep 15

Vera Therapeutics, - Trutakna Demonstrates Favorable Safety Profile Generally Comparable to Placebo

THOMSON REUTERS
·
Sep 15

Vera Therapeutics, - Plans to Submit Supplemental Bla to FDA for Full Approval in Q4 2026

THOMSON REUTERS
·
Sep 15

Vera Therapeutics Announces Trutakna™ (Atacicept-Vymj) Stabilized Egfr and Prevented Kidney Disease Progression Through Two Years in Origin 3 Final Efficacy Analysis in Iga Nephropathy

THOMSON REUTERS
·
Sep 15

Vera Therapeutics, - Trutakna Meets All Prespecified Endpoints in Origin 3 Final Efficacy Analysis

THOMSON REUTERS
·
Sep 15

Vera Therapeutics is Maintained at Overweight by JP Morgan

Dow Jones
·
Sep 08

U.S. Research Roundup-Fedex Freight Holding Company, PDF Solutions, Robinhood Markets

Reuters
·
Sep 08

Vera Therapeutics, Inc. : JP Morgan Raises Target Price to $83 from $76

THOMSON REUTERS
·
Sep 08
More